Xencor (NASDAQ:XNCR) Sets New 1-Year Low – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during trading on Monday . The stock traded as low as $13.42 and last traded at $13.60, with a volume of 76991 shares trading hands. The stock had previously closed at $13.87.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Xencor has a consensus rating of “Buy” and a consensus price target of $34.38.

Xencor Trading Down 1.3 %

The company has a fifty day simple moving average of $18.00 and a two-hundred day simple moving average of $20.56. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $947.71 million, a P/E ratio of -4.20 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its holdings in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor in the fourth quarter valued at about $34,000. GAMMA Investing LLC lifted its holdings in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV lifted its holdings in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Quarry LP lifted its holdings in shares of Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 2,108 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.